MI Barcia Martin, C. Aguilar Guisado, S. Sanchez Suarez, M. Garcia Gimeno
{"title":"2SPD-036 COVID-19期间集中异丙酚修复程序","authors":"MI Barcia Martin, C. Aguilar Guisado, S. Sanchez Suarez, M. Garcia Gimeno","doi":"10.1136/EJHPHARM-2021-EAHPCONF.19","DOIUrl":null,"url":null,"abstract":"Background and importanceBecause of the current pandemic, it was necessary to create an intensive care unit (ICU) in our hospital This meant an increase in the consumption of propofol and the associated supply problems It was necessary to develop a procedure to rationalise its use and administration Aim and objectivesTo describe the centralisation in the hospital pharmacy service of the reconditioning of propofol in bags to optimise its administration in the ICU during the COVID-19 pandemic Material and methodsThe ICU contacted the pharmacy service to express the need for higher volume presentations of propofol In response, a literature review was conducted to ascertain the possibility of reconditioning propofol in higher volume containers The stability of propofol in different primary packaging materials was reviewed to select the most appropriate The risk matrix for sterile preparations from the ‘Guide to good practice in the preparation of medicines in hospital pharmacy services’ was applied to draw up the standard working procedure and to establish the processing conditions, stability of the preparation and storage conditions A centralised propofol reconditioning procedure (CPRP) was established in the pharmacy service: under sterile conditions, transfer the propofol into an ethylene-vinyl-acetate bag to obtain a final volume of 500 mL (10 mg/mL) (using a 0 22 µm filter if the initial packaging is glass) It was sealed, labelled and packed in a photo protective bag The established stability was 7 days refrigerated or 30 hours at room temperature A descriptive retrospective study was carried out from its implementation (20 March 2020) to the date of closure of the ICU (5 May 2020) to determine the volume of reconditioned propofol and number of patients treated Data were collected from the electronic medical record and pharmacy programmes ResultsDuring this period, 258 propofol bags were produced Reconditioned propofol was dispensed to 16 patients (median age 59 years (range 41–83);62 5% men) The median number of bags per patient was 13 5 (range 3–66) Conclusion and relevanceThe CPRP in the pharmacy service increases the safety of administration, allows preparation under aseptic conditions and enables the optimisation of available stock As it contains more volume, it facilitates the work and protects the nursing staff by reducing the frequency of contact with the patient References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":"57 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"2SPD-036 Centralised propofol reconditioning procedure during COVID-19\",\"authors\":\"MI Barcia Martin, C. Aguilar Guisado, S. Sanchez Suarez, M. Garcia Gimeno\",\"doi\":\"10.1136/EJHPHARM-2021-EAHPCONF.19\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background and importanceBecause of the current pandemic, it was necessary to create an intensive care unit (ICU) in our hospital This meant an increase in the consumption of propofol and the associated supply problems It was necessary to develop a procedure to rationalise its use and administration Aim and objectivesTo describe the centralisation in the hospital pharmacy service of the reconditioning of propofol in bags to optimise its administration in the ICU during the COVID-19 pandemic Material and methodsThe ICU contacted the pharmacy service to express the need for higher volume presentations of propofol In response, a literature review was conducted to ascertain the possibility of reconditioning propofol in higher volume containers The stability of propofol in different primary packaging materials was reviewed to select the most appropriate The risk matrix for sterile preparations from the ‘Guide to good practice in the preparation of medicines in hospital pharmacy services’ was applied to draw up the standard working procedure and to establish the processing conditions, stability of the preparation and storage conditions A centralised propofol reconditioning procedure (CPRP) was established in the pharmacy service: under sterile conditions, transfer the propofol into an ethylene-vinyl-acetate bag to obtain a final volume of 500 mL (10 mg/mL) (using a 0 22 µm filter if the initial packaging is glass) It was sealed, labelled and packed in a photo protective bag The established stability was 7 days refrigerated or 30 hours at room temperature A descriptive retrospective study was carried out from its implementation (20 March 2020) to the date of closure of the ICU (5 May 2020) to determine the volume of reconditioned propofol and number of patients treated Data were collected from the electronic medical record and pharmacy programmes ResultsDuring this period, 258 propofol bags were produced Reconditioned propofol was dispensed to 16 patients (median age 59 years (range 41–83);62 5% men) The median number of bags per patient was 13 5 (range 3–66) Conclusion and relevanceThe CPRP in the pharmacy service increases the safety of administration, allows preparation under aseptic conditions and enables the optimisation of available stock As it contains more volume, it facilitates the work and protects the nursing staff by reducing the frequency of contact with the patient References and/or acknowledgementsConflict of interestNo conflict of interest\",\"PeriodicalId\":11991,\"journal\":{\"name\":\"European Journal of Hospital Pharmacy: Science and Practice\",\"volume\":\"57 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Hospital Pharmacy: Science and Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.19\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Hospital Pharmacy: Science and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.19","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景和重要性由于当前的大流行,有必要创建一个重症监护病房(ICU)医院这意味着增加消费的异丙酚和相关的供应问题有必要开发一个程序合理化使用和管理目标和objectivesTo描述医院药学服务的集中化的异丙酚整理袋来优化其政府在ICU COVID-19流行材料和methodsThe ICU联系了药房服务表示需要更大剂量的异丙酚对异丙酚在不同主要包装材料中的稳定性进行了评价,以选择最合适的包装材料。应用《医院药房药品配制良好规范指南》中的无菌制剂风险矩阵,制定了标准工作程序,并确定了加工条件。在药房服务中建立了集中异丙酚修复程序(CPRP):在无菌条件下,将异丙酚转移到乙烯-乙烯-醋酸酯袋中,最终体积为500 mL (10 mg/mL)(如果初始包装为玻璃,则使用0.22µm过滤器)。确定的稳定性为冷藏7天或室温30小时。从实施(2020年3月20日)到ICU关闭之日(2020年5月5日)进行了描述性回顾性研究,以确定修复异丙酚的量和治疗的患者人数。数据收集自电子病历和药房规划。共生产258袋异丙酚,16例患者(年龄中位数为59岁(41-83岁),62.5%为男性)使用修复异丙酚,每位患者平均使用135袋(范围3-66)结论及相关性药学服务中的CPRP提高了给药安全性,允许在无菌条件下制备,并使可用库存优化,因为它含有更多的体积。它通过减少与病人接触的频率来促进工作并保护护理人员参考文献和/或致谢利益冲突无利益冲突
2SPD-036 Centralised propofol reconditioning procedure during COVID-19
Background and importanceBecause of the current pandemic, it was necessary to create an intensive care unit (ICU) in our hospital This meant an increase in the consumption of propofol and the associated supply problems It was necessary to develop a procedure to rationalise its use and administration Aim and objectivesTo describe the centralisation in the hospital pharmacy service of the reconditioning of propofol in bags to optimise its administration in the ICU during the COVID-19 pandemic Material and methodsThe ICU contacted the pharmacy service to express the need for higher volume presentations of propofol In response, a literature review was conducted to ascertain the possibility of reconditioning propofol in higher volume containers The stability of propofol in different primary packaging materials was reviewed to select the most appropriate The risk matrix for sterile preparations from the ‘Guide to good practice in the preparation of medicines in hospital pharmacy services’ was applied to draw up the standard working procedure and to establish the processing conditions, stability of the preparation and storage conditions A centralised propofol reconditioning procedure (CPRP) was established in the pharmacy service: under sterile conditions, transfer the propofol into an ethylene-vinyl-acetate bag to obtain a final volume of 500 mL (10 mg/mL) (using a 0 22 µm filter if the initial packaging is glass) It was sealed, labelled and packed in a photo protective bag The established stability was 7 days refrigerated or 30 hours at room temperature A descriptive retrospective study was carried out from its implementation (20 March 2020) to the date of closure of the ICU (5 May 2020) to determine the volume of reconditioned propofol and number of patients treated Data were collected from the electronic medical record and pharmacy programmes ResultsDuring this period, 258 propofol bags were produced Reconditioned propofol was dispensed to 16 patients (median age 59 years (range 41–83);62 5% men) The median number of bags per patient was 13 5 (range 3–66) Conclusion and relevanceThe CPRP in the pharmacy service increases the safety of administration, allows preparation under aseptic conditions and enables the optimisation of available stock As it contains more volume, it facilitates the work and protects the nursing staff by reducing the frequency of contact with the patient References and/or acknowledgementsConflict of interestNo conflict of interest